Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial

被引：0
|
作者：
Matikas, Alexios
Gnant, Michael
Johansson, Hemming
Untch, Michael
Tsiknakis, Nikolaos
Greil, Richard
Loibl, Sibylle
Foukakis, Theodoros
Bergh, Jonas C. S.
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Karolinska Univ Hosp, Stockholm, Sweden
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] Helios Klinikum Berlin Buch, Berlin, Germany
[5] Paracelsus Med Univ, Canc Cluster Salzburg, Ctr Clin Canc & Immunol Trials, Med Dept 3,Salzburg Canc Res Inst, Salzburg, Austria
[6] GBG Forsch GmbH, Neu Isenburg, Germany
[7] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[8] Karolinska Univ Hosp, Karolinska Comprehens Canc Ctr, Breast Canc Ctr, Canc Theme, Stockholm, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
521
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Composite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer
    Puglisi, F.
    Ceppi, M.
    Gerratana, L.
    Cognetti, F.
    De Placido, S.
    Bruzzi, P.
    De laurentiis, M.
    Bisagni, G.
    Cavazzini, G.
    Durando, A.
    Turletti, A.
    Valle, E.
    Montemurro, F.
    Barni, S.
    Ardizzoni, A.
    Colantuoni, G.
    Gamucci, T.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
    Alexios Matikas
    Sara Margolin
    Mats Hellström
    Hemming Johansson
    Nils-Olof Bengtsson
    Lena Karlsson
    Per Edlund
    Per Karlsson
    Elisabet Lidbrink
    Barbro Linderholm
    Henrik Lindman
    Per Malmstrom
    Kenneth Villman
    Theodoros Foukakis
    Jonas Bergh
    Breast Cancer Research and Treatment, 2018, 168 : 349 - 355
  • [23] Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
    Matikas, Alexios
    Margolin, Sara
    Hellstrom, Mats
    Johansson, Hemming
    Bengtsson, Nils-Olof
    Karlsson, Lena
    Edlund, Per
    Karlsson, Per
    Lidbrink, Elisabet
    Linderholm, Barbro
    Lindman, Henrik
    Malmstrom, Per
    Villman, Kenneth
    Foukakis, Theodoros
    Bergh, Jonas
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 349 - 355
  • [24] Dose dense chemotherapy for early stage breast cancer
    Huds, C.
    EJC SUPPLEMENTS, 2004, 2 (03): : 119 - 119
  • [25] Estimating benefit of adjuvant chemotherapy for breast cancer patients on the individual level
    Rouzier, R.
    Bonneau, C.
    Lerebours, F.
    Falcou, M-C.
    Pierga, J-Y.
    Salomon, A.
    Guinebretiere, J-M.
    Hequet, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 21 - 22
  • [26] Dose-dense early postoperative intraperitoneal chemotherapy in ovarian cancer: Randomized, phase II trial.
    Zang, Rongyu
    Shi, Tingyan
    Jiang, Rong
    Pu, Hong
    Yang, Huijuan
    Tu, Dongsheng
    Dai, Zhiyuan
    Cai, Yulang
    Zhang, Yuqin
    Cheng, Xi
    Jia, Huixun
    Tu, Ruiqin
    Wang, Hua-ying
    Tang, Jie
    Luan, Yuting
    Cai, Shumo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer patients in a randomised trial.
    Kummel, S.
    Krocker, J.
    Kohls, A.
    Breitbach, G-P
    Budner, M.
    Keil, E.
    Hinke, A.
    Blohmer, J-U
    Elling, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S113 - S113
  • [28] RE: Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial Response
    Moebus, Volker
    Jackisch, Christian
    Schneeweiss, Andreas
    Huober, Jens
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Thomssen, Christoph
    Kurbacher, Christian
    Kuhn, Walther
    Nitz, Ulrike A.
    Runnebaum, Ingo B.
    Hinke, Axel
    Kreienberg, Rolf
    Untch, Michael
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (03):
  • [29] Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
    Del Mastro, Lucia
    Poggio, Francesca
    Blondeaux, Eva
    De Placido, Sabino
    Giuliano, Mario
    Forestieri, Valeria
    De laurentiis, Michelino
    Gravina, Adriano
    Bisagni, Giancarlo
    Rimanti, Anita
    Turletti, Anna
    Nistico, Cecilia
    Vaccaro, Angela
    Cognetti, Francesco
    Fabi, Alessandra
    Gasparro, Simona
    Garrone, Ornella
    Alicicco, Maria Grazia
    Urracci, Ylenia
    Mansutti, Mauro
    Poletti, Paola
    Correale, Pierpaolo
    Bighin, Claudia
    Puglisi, Fabio
    Montemurro, Filippo
    Colantuoni, Giuseppe
    Lambertini, Matteo
    Boni, Luca
    LANCET ONCOLOGY, 2022, 23 (12): : 1571 - 1582
  • [30] Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer
    Mayer, Erica L.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) : 1198 - 1200
12345